Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
OncoTherapy Science Inc Announces Start of Phase I Clinical Trial of OTS167
OncoTherapy Science Inc announced the start of the phase I clinical trial of OTS167, which is a kind of molecular target drug targeted at kinase Maternal Embryonic Leucine zipper Kinase.
Latest Developments for OncoTherapy Science Inc
- OncoTherapy Science Inc Lowers Consolidated Full-year Outlook for FY 2013
- OncoTherapy Science, Inc. Announces Result of Phase Ⅱ/Ⅲ Clinical Trial for Elpamotide
- OncoTherapy Science, Inc. Receives Patent in Japan and United States
- OncoTherapy Science, Inc. Raises Consolidated Full-year Outlook for FY Ended March 2012
Latest Key Developments in Biotechnology
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Share this
- Link this
- Digg this
Follow Reuters